Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming
Sebastian Zimmer,Alena Grebe,Siril S Bakke,Niklas Bode,Bente Halvorsen,Thomas Ulas,Mona Skjelland,Dominic De Nardo,Larisa I Labzin,Anja Kerksiek,Chris Hempel,Michael T Heneka,Victoria Hawxhurst,Michael L Fitzgerald,Jonel Trebicka,Ingemar Björkhem,Jan-Åke Gustafsson,Marit Westerterp,Alan R Tall,Samuel D Wright,Terje Espevik,Joachim L Schultze,Georg Nickenig,Dieter Lütjohann,Eicke Latz,Siril S. Bakke,Larisa I. Labzin,Michael T. Heneka,Michael L. Fitzgerald,Alan R. Tall,Samuel D. Wright,Joachim L. Schultze
DOI: https://doi.org/10.1126/scitranslmed.aad6100
IF: 17.1
2016-04-06
Science Translational Medicine
Abstract:The cyclic oligosaccharide 2-hydroxypropyl-β-cyclodextrin facilitates atheroprotective mechanisms through oxysterol-mediated reprogramming of macrophages.
cell biology,medicine, research & experimental